1. Ogurtsova K, da Rocha Fernandes J, Huang Y, Linnenkamp U, Guariguata L, Cho N, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017; 128:40-50.
2. Herman WH. The Global burden of diabetes: An overview. Diabetes mellitus in developing countries and underserved communities: Springer 2017. p. 1-5.
3. Madonna R, De Caterina R. Cellular and molecular mechanisms of vascular injury in diabetes—part I: pathways of vascular disease in diabetes. Vascul Pharmacol 2011; 54:68-74.
4. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013; 93:137-188.
5. Group DPPR. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention. Diabetes Care 2012; 35:723-730.
6. Evert AB, Boucher JL, Cypress M, Dunbar SA, Franz MJ, Mayer-Davis EJ, et al. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care 2013; 36:3821-3842.
7. Ley SH, Hamdy O, Mohan V, Hu FB. Prevention and management of type 2 diabetes: dietary components and nutritional strategies. Lancet. 2014; 383:1999-2007.
8. Hyppönen E, Läärä E, Reunanen A, Järvelin M-R, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet. 2001; 358:1500-1503.
9. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007; 92:2017-2029.
10. Kaur H, Donaghue KC, Chan AK, Benitez-Aguirre P, Hing S, Lloyd M, et al. Vitamin D deficiency is associated with retinopathy in children and adolescents with type 1 diabetes. Diabetes Care 2011; 34:1400-1402.
11. Shehab D, Al‐Jarallah K, Mojiminiyi O, Al Mohamedy H, Abdella N. Does Vitamin D deficiency play a role in peripheral neuropathy in Type 2 diabetes? Diabet Med 2012; 29:43-49.
12. Diaz VA, Mainous AG, Carek PJ, Wessell AM, Everett CJ. The association of vitamin D deficiency and insufficiency with diabetic nephropathy: implications for health disparities. J Am Board Fam Med 2009; 22:521-527.
13. Olfert ED, Cross BM, McWilliam AA. Guide to the care and use of experimental animals: Canadian Council on Animal Care Ottawa; 1993.
14. Husemoen LLN, Thuesen BH, Fenger M, Jørgensen T, Glümer C, Svensson J, et al. Serum 25 (OH) D and type 2 diabetes association in a general population. Diabetes Care 2012; 35:1695-1700.
15. Zipitis CS, Akobeng AK. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child 2008; 93:512-517.
16. Park S, Kim DS, Kang S. Vitamin D deficiency impairs glucose-stimulated insulin secretion and increases insulin resistance by reducing PPAR-γ expression in nonobese Type 2 diabetic rats. J Nutr Biochem 2016; 27:257-265.
17. Jayanarayanan S, Anju TR, Smijin S, Paulose CS. Vitamin D 3 supplementation increases insulin level by regulating altered IP3 and AMPA receptor expression in the pancreatic islets of streptozotocin-induced diabetic rat. J Nutr Biochem 2015; 26:1041-1049.
18. Yang Z, Liu F, Qu H, Wang H, Xiao X, Deng H. 1, 25 (OH) 2 D 3 protects β cell against high glucose-induced apoptosis through mTOR suppressing. Mol Cell Endocrinol 2015; 414:111-119.
19. Manna P, Jain SK. Vitamin D up-regulates glucose transporter 4 (GLUT4) translocation and glucose utilization mediated by cystathionine-γ-lyase (CSE) activation and H2S formation in 3T3L1 adipocytes. J Biol Chem 2012; 287:42324-42332.
20. Enciso PL, Wang L, Kawahara Y, Sakamoto S, Shimada S, Takeichi Y, et al. Dietary vitamin D 3 improves postprandial hyperglycemia in aged mice. Biochem Biophys Res Commun 2015; 461:165-171.
21. Beisswenger PJ, Howell SK, Russell GB, Miller ME, Rich SS, Mauer M. Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products. Diabetes Care 2013; 36:3234-3239.
22. Sveen KA, Karimé B, Jørum E, Mellgren SI, Fagerland MW, Monnier VM, et al. Small-and large-fiber neuropathy after 40 years of type 1 diabetes. Diabetes Care 2013; 36:3712-3717.
23. Choudhuri S, Dutta D, Sen A, Chowdhury IH, Mitra B, Mondal LK, et al. Role of N–epsilon-carboxy methyl lysine, advanced glycation end products and reactive oxygen species for the development of nonproliferative and proliferative retinopathy in type 2 diabetes mellitus. Mol Vis 2013;19:100-13.
24. Ramasamy R, Vannucci SJ, Du Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005; 15:16-28.
25. Brouwers O, Niessen PM, Ferreira I, Miyata T, Scheffer PG, Teerlink T, et al. Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats. J Biol Chem 2011; 286:1374-1380.
26. Kawai T, Takei I, Tokui M, Funae O, Miyamoto K, Tabata M, et al. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N ɛ-carboxymethyl lysine. J Diabetes Complications 2010; 24:424-432.
27. Hashimoto Y, Yamagishi SI, Mizukami H, Yabe‐Nishimura C, Lim SW, Kwon HM, et al. Polyol pathway and diabetic nephropathy revisited: early tubular cell changes and glomerulopathy in diabetic mice overexpressing human aldose reductase. J Diabetes Investig 2011; 2:111-122.
28. Akimoto Y, Miura Y, Toda T, Wolfert MA, Wells L, Boons G-J, et al. Morphological changes in diabetic kidney are associated with increased O-GlcNAcylation of cytoskeletal proteins including α-actinin 4. Clin Proteomics 2011; 8:15.
29. Park SY, Ryu J, Lee W. O-GlcNAc modification on IRS-1 and Akt2 by PUGNAc inhibits their phosphorylation and induces insulin resistance in rat primary adipocytes. Exp Mol Med 2005; 37:220-229.
30. Inbathamizh L, Padmini E. In silico studies on the inhibitory effects of calcitriol and 5, 5’-dithiobis-2-nitrobenzoic acid on human glucosaminyl N-acetyl transferase 1 activity. Asian J Exp Biol Sci 2012; 3:14-21.